Persistent drop in confidence following US recommended pause of Ad26.COV2.S vaccine administration

The Janssen COVID-19 vaccine came to market in February 2021 as the first non-mRNA and first single-dose formula approved for use in the US. In April 2021, a temporary pause was recommended for the vaccine after the discovery of rare but serious post-vaccination side-effects. We fielded a large-scal...

Descripción completa

Detalles Bibliográficos
Autores principales: Rader, Benjamin, Chiang, Molly E., Kriner, Douglas L., Weintraub, Rebecca L., Brownstein, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692206/
https://www.ncbi.nlm.nih.gov/pubmed/36443155
http://dx.doi.org/10.1016/j.vaccine.2022.11.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692206/
https://www.ncbi.nlm.nih.gov/pubmed/36443155
http://dx.doi.org/10.1016/j.vaccine.2022.11.035

Ejemplares similares